000 06014cam a2200577Ii 4500
001 ocn913829107
003 OCoLC
005 20190328114812.0
006 m o d
007 cr cnu|||unuuu
008 150715s2015 ne ob 000 0 eng d
040 _aN$T
_beng
_erda
_epn
_cN$T
_dOPELS
_dN$T
_dEBLCP
_dYDXCP
_dIDEBK
_dCDX
_dDEBSZ
_dOCLCF
_dOCLCQ
_dCASUM
_dOCLCO
_dMERER
_dOCLCO
_dOCLCQ
_dOCLCA
_dWRM
_dU3W
_dOCLCO
_dD6H
_dOCLCQ
_dWYU
_dOCLCA
_dCUY
_dLOA
_dZCU
_dMERUC
_dOCLCO
_dICG
_dUSU
_dOCLCO
_dK6U
_dCOCUF
_dOCLCQ
_dDKC
_dOCLCO
019 _a914148150
_a1066572097
020 _a9780128035573
_q(electronic bk.)
020 _a0128035579
_q(electronic bk.)
020 _z9780128035191
035 _a(OCoLC)913829107
_z(OCoLC)914148150
_z(OCoLC)1066572097
050 4 _aRS403
060 0 0 _a2015 J-592
060 1 0 _aQV 785
072 7 _aMED
_x071000
_2bisacsh
082 0 4 _a615.1/9
_223
100 1 _aRedasani, Vivekkumar K.,
_eauthor.
245 1 0 _aProdrug design : perspectives, approaches and applications in medicinal chemistry /
_h[electronic resource]
_cVivekkumar K. Redasani, Sanjay B. Bari.
264 1 _a[Amsterdam] :
_bAcademic Press is an imprint of Elsevier,
_c2015.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
588 0 _aOnline resource; title from PDF title page (ScienceDirect, viewed July 16, 2015).
504 _aIncludes bibliographical references.
505 0 _aFront Cover; Prodrug Design; Copyright Page; Dedication; Contents; Preface; 1 Introduction; 1.1 Background; 1.2 Drug Development; 1.3 The Drug Discovery Process; 1.3.1 Goal of Drug Discovery; 1.3.2 Constraints in Drug Discovery; 1.4 Current Scenario in Prodrug Research; 1.5 Need of the Study; References; 2 Concept of Prodrug; 2.1 Concept of Prodrug; 2.2 Undesirable Properties Associated with Drug Molecules; 2.3 Prodrug Design: Past to Present; 2.4 Definitions of Prodrug; 2.5 Rationale for the Use of Prodrugs; 2.6 Targeted Prodrug Design; 2.7 Double Prodrug Concept; 2.8 Steps in Prodrug Design.
505 8 _a2.8.1 Hard Drugs2.8.2 Soft Drugs; 2.9 Objectives in Prodrug Research; 2.9.1 Pharmaceutical Objectives; 2.9.2 Pharmacokinetic Objectives; 2.9.3 Pharmacodynamic Objectives; 2.10 Evaluation of Prodrugs; 2.10.1 Physiochemical Parameters; 2.10.2 Pharmacokinetics Profile; 2.10.3 Pharmacodynamics; References; 3 Types of Prodrugs; 3.1 Classification of Prodrugs; 3.1.1 Research-Related Criteria; 3.1.2 Chemical Criteria; 3.1.2.1 Carrier-Linked Prodrug; 3.1.2.2 Mutual Prodrug; 3.1.2.3 Bioprecursor Prodrug; 3.1.2.3.1 Oxidative Bioactivations; 3.1.2.3.2 Reductive Bioactivations; 3.1.2.4 Polymeric Prodrug.
505 8 _a3.1.2.5 Tripartate Prodrug3.2 Criteria for Prodrug; 3.3 Classifying Prodrugs; 3.4 Challenges and Limitations in Prodrug Design; References; 4 Approaches for Prodrugs; 4.1 Promoiety; 4.2 Functional Groups Compliant for Design of Prodrug; 4.3 Bioreversible Derivatives for Various Functional Groups; 4.4 Phosphate Esters as Prodrugs of Hydroxyl or Amine Functionalities; 4.5 Amides as Prodrugs of Carboxylic Acids and Amines; 4.6 Prodrug for Amides, Imides, and Other Acidic Compounds; 4.6.1 N-Mannich Bases and Acyloxy Derivatives; 4.6.2 N-Acyl Derivatives; 4.6.3 N-Hydroxy Methyl Derivatives.
505 8 _a4.7 Prodrugs for Amines4.7.1 N-(Acyloxy Alkoxy Carbonyl) Derivatives and Amide Derivatives; 4.7.2 Oxazolidines; 4.8 Prodrugs with Carbonyl groups; 4.8.1 Thiazolidines; 4.8.2 Enol Esters; 4.9 Types of Promoieties Used in Designing of Prodrugs; 4.9.1 Amino Acids; 4.9.2 Polysaccharides; 4.9.3 Alcohols; 4.9.4 Phytophenols; 4.9.5 Amines; 4.9.6 Polymers; 4.9.6.1 Requirements for Selecting Polymers as Candidate Drug Carriers; 4.9.6.2 Classification of Polymers Used for Bioconjugation; 4.10 Coupling of Drug and Polymer Through Spacers; References; 5 Applications; 5.1 Applications of Prodrug Designing.
505 8 _a5.1.1 Masking Taste and Odor5.1.2 Minimizing Pain at Injection Site; 5.1.3 Alteration of Drug Solubility; 5.1.4 Enhancement of Chemical Stability; 5.1.5 Prodrugs to Overcome Absorption Problems; 5.1.5.1 Enhancement of Oral Absorption; 5.1.5.2 Enhancement of Ophthalmic Absorption; 5.1.5.3 Enhancement of Percutaneous Absorption; 5.1.6 Prevention of Presystemic Metabolism; 5.1.7 Longer Duration of Action; 5.1.8 To Diminish Local and Systemic Toxicity of Drugs/Reduction of GI Irritability; 5.1.9 Site-Specific Drug Delivery; 5.1.10 Prodrug for Slow and Prolonged Release (Sustained Drug Action).
520 _aProdrug Design: Perspectives, Approaches and Applications in Medicinal Chemistry provides a focused overview of this critical area of drug discovery, as that continuous process strives not only to discover new drug compounds but also to modify the existing ones. This valuable primer supports this mission of drug development and its goal of reducing undesired effects and improving therapeutic effectiveness of drug compounds. Providing a unique compilation of data, insightful case studies, and review of existing literature in the area, the book will promote innovation in medicinal and pharmaceu.
650 0 _aPharmaceutical chemistry.
650 0 _aDrugs
_xDesign.
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aDrugs
_xDesign.
_2fast
_0(OCoLC)fst00898790
650 7 _aPharmaceutical chemistry.
_2fast
_0(OCoLC)fst01060115
650 2 _aProdrugs.
_0(DNLM)D011355
650 2 _aDrug Design.
_0(DNLM)D015195
655 7 _aElectronic books.
_2lcgft
655 4 _aElectronic books.
700 1 _aBari, Sanjay B.,
_eauthor.
776 0 8 _iPrint version:
_aRedasani, Vivekkumar K.
_tProdrug Design : Perspectives, Approaches and Applications in Medicinal Chemistry.
_dBurlington : Elsevier Science, �2015
_z9780128035191
_w(DLC) 2017287392
_w(OCoLC)909329794
856 4 0 _3ScienceDirect
_uhttp://www.sciencedirect.com/science/book/9780128035191
856 4 0 _3ScienceDirect
_uhttps://www.sciencedirect.com/science/book/9780128035191
999 _c247115
_d247115